ReviewExperimental and therapeutic medicine2026
Immune cross talk and therapeutic advances in lactate metabolism in the tumor microenvironment (Review).
Review in Experimental and therapeutic medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The excessive buildup of lactic acid within the tumor microenvironment (TME) serves as a hallmark of metabolic reprogramming in cancer. New studies have revealed that lactic acid is an energy metabolic product and a core biological signal that regulates the malignant process of tumors. It plays multiple roles in metabolic reprogramming, protein lactate modification, immune escape, drug resistance generation, epigenetic regulation and metastatic spread. It also has significant negative implications for patient survival. In this review, the advances in understanding the metabolic mechanisms of lactate in the TME and its crosstalk with various of immune cells were systematically reviewed and its therapeutic potential in the following ways was explored: Targeting lactate synthesis (e.g., lactate dehydrogenase inhibitors); interfering with lactate catabolism (e.g., monocarboxylate transporter blockers); and regulating lactate shuttling (microenvironmental cell-to-cell communication). The review aimed to identify new targets and ideas for anticancer strategies by analyzing the lactate metabolic network.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.